Not available
Quote | Astellas Pharma Inc. ADR (OTCMKTS:ALPMY)
Last: | $9.805 |
---|---|
Change Percent: | 0.1% |
Open: | $9.81 |
Close: | $9.805 |
High: | $9.83 |
Low: | $9.78 |
Volume: | 51,511 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Astellas Pharma Inc. ADR (OTCMKTS:ALPMY)
2024-06-01 17:52:36 ET More on Corbus Pharmaceuticals Neutral On Corbus Pharmaceuticals' Financials And Clinical Progress In Oncology Corbus Pharmaceuticals a new outperform at RBC on cancer, obesity assets Seeking Alpha’s Quant Rating on Corbus Pharmaceutical...
2024-05-31 13:04:02 ET More on Astellas Pharma Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript Astellas Pharma partners with YASKAWA for innovative cell therapy Astellas Pharma Non-GAAP EPS of ¥84.19, revenue of ¥1603.67B; initiates FY24 guida...
Message Board Posts | Astellas Pharma Inc. ADR (OTCMKTS:ALPMY)
Subject | By | Source | When |
---|---|---|---|
$ALPMY Lets go go go go... Up up and away we go. | SPORT19 | investorshub | 07/02/2023 2:22:09 PM |
bears and bulls | jtrenee89 | investorshub | 07/01/2023 10:34:52 PM |
Thoughts on where this is headed? | rdfdr1 | investorshub | 06/29/2023 4:31:26 PM |
bears and bulls | Sam0 | investorshub | 06/27/2023 3:56:52 AM |
$ALPMY and the shorts continue | johnsyn | investorshub | 06/22/2023 2:00:01 PM |
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc. ADR Company Name:
ALPMY Stock Symbol:
OTCMKTS Market:
U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE PR Newswire If approved, the investigational therapy would offer a new treatment option for patients with advanced gastric and gastroesophageal junction canc...
Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies PR Newswire - Focuses on digitizing cell manufacturing processes through robotics technology TOKYO ,...
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting PR Newswire 16 abstracts feature new data and post-hoc analyses of pivotal trials across several types of hard-to-treat cancers TOKYO , May 13, 2024 /PRNe...